PIN28 Comparative Effectiveness of Triple Therapy Versus Dual Therapy for Chronic Hepatitis C Virus Infection in Kazakhstan
No Thumbnail Available
Date
2013-11-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Currently, 23 thousand people (registered) are suffering from Hepatitis C in Germany (more 60% genotype 1). TThe licensing of direct-acting antivirals heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. Clinical studies showed a significant increase in sustained virological response rates from 38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly introduced triple therapy with Telaprevir (TVR+PR) compared to dual therapy (PR) for the treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated patients.
Description
Keywords
Citation
A. Almadiyeva, A. Kostyuk, T. Nurgozhin, PIN28 - Comparative Effectiveness of Triple Therapy Versus Dual Therapy for Chronic Hepatitis C Virus Infection in Kazakhstan, In Value in Health, Volume 16, Issue 7, 2013, Page A345